Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
Olivier Mir(Institut Gustave Roussy), Étienne Minvielle(Centre National de la Recherche Scientifique), A. Fourcade(Institut Gustave Roussy), Delphine Mathivon(Institut Gustave Roussy), David Malka(Inserm), Stéphane de Botton(Université Paris-Saclay), Mario Di Palma(Institut Gustave Roussy), Marie Ferrua(Institut Gustave Roussy), David Planchard(Université Paris-Saclay), Vanessa Puglisi(Institut Gustave Roussy), Éric Baudin(Institut Gustave Roussy), Patricia Pautier(Université Paris-Saclay), Florian Scotté(Université Paris-Saclay), Laurence Albigès(Université Paris-Saclay), M. Guillet(Institut Gustave Roussy), Adeline Duflot-Boukobza(Institut Gustave Roussy), Suzette Delaloge(Institut Gustave Roussy), Sarah Dumont(Institut Gustave Roussy), Caroline Robert(Institut Gustave Roussy), May Abbas(Institut Gustave Roussy), François Lemare(Institut Gustave Roussy)
Cited by 138
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k